204 related articles for article (PubMed ID: 37855891)
1. Dietary approaches to stop hypertension (DASH) diet improves hepatic fibrosis, steatosis and liver enzymes in patients with non-alcoholic fatty liver disease: a randomized controlled trial.
Sangouni AA; Nadjarzadeh A; Rohani FS; Sharuni F; Zare Z; Rahimpour S; Hojjat H; Hosseinzadeh M
Eur J Nutr; 2024 Feb; 63(1):95-105. PubMed ID: 37855891
[TBL] [Abstract][Full Text] [Related]
2. The effect of a fruit-rich diet on liver biomarkers, insulin resistance, and lipid profile in patients with non-alcoholic fatty liver disease: a randomized clinical trial.
Alami F; Alizadeh M; Shateri K
Scand J Gastroenterol; 2022 Oct; 57(10):1238-1249. PubMed ID: 35710164
[TBL] [Abstract][Full Text] [Related]
3. Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C--a randomized trial.
Rusu E; Jinga M; Enache G; Rusu F; Dragomir AD; Ancuta I; Draguţ R; Parpala C; Nan R; Sima I; Ateia S; Stoica V; Cheţa DM; Radulian G
Nutr J; 2013 Aug; 12():119. PubMed ID: 23941362
[TBL] [Abstract][Full Text] [Related]
4. Gamma-glutamyl transpeptidase elevation is associated with metabolic syndrome, hepatic steatosis, and fibrosis in patients with nonalcoholic fatty liver disease: A community-based cross-sectional study.
Chen LW; Huang MS; Shyu YC; Chien RN
Kaohsiung J Med Sci; 2021 Sep; 37(9):819-827. PubMed ID: 34002481
[TBL] [Abstract][Full Text] [Related]
5. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.
Katsagoni CN; Papatheodoridis GV; Ioannidou P; Deutsch M; Alexopoulou A; Papadopoulos N; Papageorgiou MV; Fragopoulou E; Kontogianni MD
Br J Nutr; 2018 Jul; 120(2):164-175. PubMed ID: 29947322
[TBL] [Abstract][Full Text] [Related]
6. The effect of daily consumption of probiotic yogurt on liver enzymes, steatosis and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD): study protocol for a randomized clinical trial.
Ebrahimi-Mousavi S; Alavian SM; Sohrabpour AA; Dashti F; Djafarian K; Esmaillzadeh A
BMC Gastroenterol; 2022 Mar; 22(1):102. PubMed ID: 35255811
[TBL] [Abstract][Full Text] [Related]
7. The effect of the dietary approaches to stop hypertension diet on total antioxidant capacity, superoxide dismutase, catalase, and body composition in patients with non-alcoholic fatty liver disease: a randomized controlled trial.
Zare Z; Hosseinzadeh M; Sharuni F; Rohani FS; Hojjat H; Rahimpour S; Madadizadeh F; Zavar Reza J; Wong A; Nadjarzadeh A
Front Nutr; 2023; 10():1163516. PubMed ID: 37927493
[TBL] [Abstract][Full Text] [Related]
8. Effect of a moderately carbohydrate-restricted diet on liver enzymes, steatosis and fibrosis in normal-weight individuals with non-alcoholic fatty liver disease: study protocol for a parallel randomised controlled clinical trial.
Dashti F; Alavian SM; Sohrabpour AA; Mousavi SE; Keshavarz SA; Esmaillzadeh A
BMJ Open; 2023 Apr; 13(4):e063988. PubMed ID: 37117000
[TBL] [Abstract][Full Text] [Related]
9. Effect of garlic powder supplementation on hepatic steatosis, liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease: a double-blind randomised controlled clinical trial.
Sangouni AA; Mohammad Hosseini Azar MR; Alizadeh M
Br J Nutr; 2020 Aug; 124(4):450-456. PubMed ID: 32312333
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis.
Fatima K; Moeed A; Waqar E; Atif AR; Kamran A; Rizvi H; Suri NF; Haider H; Shuja SH; Khalid M; Minhas AMK
Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101816. PubMed ID: 34607067
[TBL] [Abstract][Full Text] [Related]
11. Whole-grain consumption and its effects on hepatic steatosis and liver enzymes in patients with non-alcoholic fatty liver disease: a randomised controlled clinical trial.
Dorosti M; Jafary Heidarloo A; Bakhshimoghaddam F; Alizadeh M
Br J Nutr; 2020 Feb; 123(3):328-336. PubMed ID: 31685037
[TBL] [Abstract][Full Text] [Related]
12. A hypocaloric high-protein diet supplemented with β-cryptoxanthin improves non-alcoholic fatty liver disease: a randomized controlled trial.
Haidari F; Hojhabrimanesh A; Helli B; Seyedian SS; Ahmadi-Angali K; Abiri B
BMC Gastroenterol; 2020 Oct; 20(1):349. PubMed ID: 33081717
[TBL] [Abstract][Full Text] [Related]
13. The effects of DASH diet on weight loss and metabolic status in adults with non-alcoholic fatty liver disease: a randomized clinical trial.
Razavi Zade M; Telkabadi MH; Bahmani F; Salehi B; Farshbaf S; Asemi Z
Liver Int; 2016 Apr; 36(4):563-71. PubMed ID: 26503843
[TBL] [Abstract][Full Text] [Related]
14. The Effects of Extra Virgin Olive Oil on Alanine Aminotransferase, Aspartate Aminotransferase, and Ultrasonographic Indices of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Patients Undergoing Low Calorie Diet.
Shidfar F; Bahrololumi SS; Doaei S; Mohammadzadeh A; Gholamalizadeh M; Mohammadimanesh A
Can J Gastroenterol Hepatol; 2018; 2018():1053710. PubMed ID: 29850450
[TBL] [Abstract][Full Text] [Related]
15. The effect of DASH diet on atherogenic indices, pro-oxidant-antioxidant balance, and liver steatosis in obese adults with non-alcoholic fatty liver disease: A double-blind controlled randomized clinical trial.
Badali T; Arefhosseini S; Rooholahzadegan F; Tutunchi H; Ebrahimi-Mameghani M
Health Promot Perspect; 2023; 13(1):77-87. PubMed ID: 37309438
[No Abstract] [Full Text] [Related]
16. Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial.
Namkhah Z; Naeini F; Mahdi Rezayat S; Mehdi Yaseri ; Mansouri S; Javad Hosseinzadeh-Attar M
Int J Clin Pract; 2021 Nov; 75(11):e14852. PubMed ID: 34516703
[TBL] [Abstract][Full Text] [Related]
17. The effects of grape seed extract supplementation on cardiovascular risk factors, liver enzymes and hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
Ghanbari P; Raiesi D; Alboebadi R; Zarejavid A; Dianati M; Razmi H; Bazyar H
BMC Complement Med Ther; 2024 May; 24(1):192. PubMed ID: 38755622
[TBL] [Abstract][Full Text] [Related]
18. Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markers.
Chan WK; Sthaneshwar P; Nik Mustapha NR; Mahadeva S
PLoS One; 2014; 9(9):e105903. PubMed ID: 25184298
[TBL] [Abstract][Full Text] [Related]
19. Adherence to the dietary approaches to stop hypertension diet and non-alcoholic fatty liver disease.
Sun Y; Chen S; Zhao X; Wang Y; Lan Y; Jiang X; Gao X; Wu S; Wang L
Liver Int; 2022 Apr; 42(4):809-819. PubMed ID: 34990079
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of the pomegranate extract in improving hepatokines and serum biomarkers of non-alcoholic fatty liver disease: A randomized double blind clinical trial.
Jafarirad S; Goodarzi R; Mohammadtaghvaei N; Dastoorpoor M; Alavinejad P
Diabetes Metab Syndr; 2023 Jan; 17(1):102693. PubMed ID: 36535123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
